News
In June of 2007, Articular
Engineering expands its drug discovery
product
offering to include synovial fluid and ARC™ pellet cultures. ARC™
pellet culture combines the phenotype stability and extracellular
matrix production of alginate bead culture with the convenience of
monolayer culture.
In March of 2007, Articular
Engineering enters a collaborative agreement with Northland
Laboratories (www.Northlandlabs.com)
for the production of all cell and tissue based drug discovery
products.
2006
In April of 2006, Articular Engineering expands its drug discovery product offering to include synovial cells and tissue.
In March of 2006,
a poster entitled ‘The effect of human serum in the production of
engineered human cartilage
constructs using the alginate-recovered chondrocyte
method’ was presented at the 52nd annual meeting of the
Orthopaedic
Research Society in Chicago Illinois. (www.ors.org)
In January of
2006, Articular Engineering expands its drug discovery product
offering to include native cartilage
and disc tissues and isolated
cartilage and disc cells in addition to ARC™ cartilage and disc
products.
2005
In November of
2005, a paper describing the alginate-recovered-chondrocyte
(ARC™) method entitled
“Osteogenic protein-1
promotes the formation of tissue-engineered cartilage using the
alginate-recovered-chondrocyte method” was published in the Journal of
Osteoarthritis and Cartilage.
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=16324853)
2004
In August of
2004, Articular Engineering was awarded a Phase II SBIR grant
from the National Science
Foundation to help develop its ARC™ tissue for drug
discovery program. ( http://www.nsf.gov)
In May of 2004, Dr.
James Poser joined Articular Engineering as President and CEO.
In
March of 2004, a poster entitled ‘Age-related
changes in the biochemical properties of a scaffold-free
engineered human cartilage
tissue-challenge to the age limitation’ was presented at the 50th
annual meeting of the Orthopaedic
Research Society in San Francisco California. (www.ors.org)
In January 2004,
a paper describing the alginate-recovered-chondrocyte (ARC™) method
entitled
“Tissue-engineered human nasal
septal cartilage using the alginate-recovered-chondrocyte method” was
published in Laryngoscope.
(http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=14709992)
2003
In September of
2003, Articular Engineering was awarded a Phase I SBIR grant
from the National Institute of
Arthritis and
Musculoskeletal and Skin Diseases
(NIAMS) at the National Institutes of Health to help develop
ARC™ cartilage as an allogenic implant to
repair cartilage defects. ( http://www.nih.gov)
In August of 2003, a paper describing the method to fabricate constructs that exhibit stratified features of normal articular cartilage using "alginate-recovered-chondrocyte method, entitled “Tissue engineering of stratified articular cartilage from chondrocyte subpopulations” was published in Osteoarthritis and Cartilage.
In July of 2003, a paper describing the alginate-recovered-chondrocyte (ARC™) method entitled “A novel two-step method for the formation of tissue-engineering cartilage by mature bovine chondrocytes: the alginate-recovered-chondrocyte (ARC) method” was published in the Journal of Orthopaedic research.
In July of 2003,
Articular Engineering was awarded a Phase I SBIR grant from the
National Science Foundation
to help develop its ARC™ tissue for drug
discovery program.
(http://www.nsf.gov)
2002
In September of
2002, Articular engineering announced the issuance of United
States Patent number 6,451,060
entitled "Cartilage matrix and in vitro production of transplantable
cartilage tissue". This patent further expands the
claims made in United States
Patent number 6,197,061. (http://www.uspto.gov/)
In July of 2002,
Articular Engineering was awarded a Phase I SBIR grant from the
National Science Foundation
to help develop ARC™ Cartilage as an autogenic
implant to repair cartilage defects. ( http://www.nsf.gov)
In February 2002,
a comparison of ARC™ cartilage with explant cultures was presented at a
talk at the 48th
annual meeting of the Orthopaedic
Research Society in Dallas Texas. (www.ors.org)
In January of 2002,
Articular Engineering announced the sale of bovine ARC™ cartilage
tissue for drug
discovery. ARC™ cartilage for
drug discovery provides a defined culture system to test factors
capable of interfering with the
catabolic and anabolic aspects of cartilage matrix turnover. The ARC™
culture system represents the state of the
art in tissue engineering, and addresses many of the
shortcomings of monolayer and explant culture systems.
(Drug
Discovery Division)
2001
In March of 2001,
Articular engineering announced the issuance of United States Patent
number 6,197,061
entitled "In vitro production of
transplantable cartilage tissue cohesive cartilage produced thereby,
and method for
the surgical repair of cartilage damage". This patent technology
involves a two-step culture method designed to
retain the chondrocytic phenotype
thereby promoting production of normal cartilage tissue. (www.uspto.gov)
1999
In September of
1999, Articular Engineering opens the doors of its new
research and development facility north of
Chicago, in Northbrook Illinois.
©Copyright 2006 Articular Engineering All rights reserved